IL246253A0 - Use of an opioid receptor antagonist with kappa activity and vortioxetine for the treatment of depressive disorder with melancholic features - Google Patents
Use of an opioid receptor antagonist with kappa activity and vortioxetine for the treatment of depressive disorder with melancholic featuresInfo
- Publication number
- IL246253A0 IL246253A0 IL246253A IL24625316A IL246253A0 IL 246253 A0 IL246253 A0 IL 246253A0 IL 246253 A IL246253 A IL 246253A IL 24625316 A IL24625316 A IL 24625316A IL 246253 A0 IL246253 A0 IL 246253A0
- Authority
- IL
- Israel
- Prior art keywords
- vortioxetine
- kappa
- activity
- treatment
- receptor antagonist
- Prior art date
Links
- 208000020401 Depressive disease Diseases 0.000 title 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 239000003401 opiate antagonist Substances 0.000 title 1
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title 1
- 229960002263 vortioxetine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201300710 | 2013-12-20 | ||
| DKPA201400590 | 2014-10-16 | ||
| PCT/EP2014/078515 WO2015091833A1 (en) | 2013-12-20 | 2014-12-18 | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL246253A0 true IL246253A0 (en) | 2016-07-31 |
Family
ID=52146489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL246253A IL246253A0 (en) | 2013-12-20 | 2016-06-15 | Use of an opioid receptor antagonist with kappa activity and vortioxetine for the treatment of depressive disorder with melancholic features |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10376506B2 (enExample) |
| EP (1) | EP3082815B1 (enExample) |
| JP (1) | JP6448645B2 (enExample) |
| KR (1) | KR20160093025A (enExample) |
| CN (1) | CN105828821B (enExample) |
| AU (1) | AU2014368548B2 (enExample) |
| CA (1) | CA2933733A1 (enExample) |
| CL (1) | CL2016001570A1 (enExample) |
| ES (1) | ES2694352T3 (enExample) |
| IL (1) | IL246253A0 (enExample) |
| MX (1) | MX368870B (enExample) |
| RU (1) | RU2679661C1 (enExample) |
| SG (1) | SG11201604944PA (enExample) |
| WO (1) | WO2015091833A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018003930A2 (pt) * | 2016-07-01 | 2018-09-25 | H Lundbeck As | regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| JP7549576B2 (ja) | 2018-11-06 | 2024-09-11 | パーデュー、ファーマ、リミテッド、パートナーシップ | オピオイドアンタゴニストを送達するための組成物及び方法 |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| TW202400135A (zh) | 2022-03-07 | 2024-01-01 | 美商健生醫藥公司 | 包含阿替卡普蘭之組成物 |
| TW202547487A (zh) * | 2024-03-18 | 2025-12-16 | 學校法人東京理科大學 | 失樂症的治療或預防用醫藥組成物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013740A (en) | 1990-03-22 | 1991-05-07 | Hillel Glover | Method for treating emotional numbness and coma |
| US5028612A (en) | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| US6528518B2 (en) * | 2000-12-21 | 2003-03-04 | The Mclean Hospital Corporation | Treatment of depression with kappa receptor antagonists |
| US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
| PL368612A1 (en) * | 2001-08-14 | 2005-04-04 | Biotie Therapies Corporation | Method of treating alcoholism or alcohol abuse |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| DK1485051T3 (da) * | 2002-03-20 | 2008-09-08 | Euro Celtique Sa | Fremgangsmåde til indgivelse af buprenorphin til behandling af depression |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US20070179168A1 (en) * | 2005-11-28 | 2007-08-02 | Orexigen Therapeutics, Inc. | Methods of treating anxiety disorders |
| CN101432011A (zh) * | 2006-02-27 | 2009-05-13 | 亚历山大·米哈洛 | 通过诱导逆适应调节神经递质系统的方法 |
| WO2008066916A1 (en) | 2006-11-30 | 2008-06-05 | The Mclean Hospital Corporation | Methods for the treatment of mood disorders |
| DE502007002185D1 (de) * | 2006-04-04 | 2010-01-14 | Emodys Gmbh | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
| US20070259939A1 (en) * | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
| KR101627901B1 (ko) | 2006-06-16 | 2016-06-13 | 하. 룬트벡 아크티에 셀스카브 | 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진 |
| TW200848411A (en) | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| TW200932225A (en) * | 2007-12-14 | 2009-08-01 | Lundbeck & Co As H | 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine |
| MY158251A (en) | 2009-05-25 | 2016-09-30 | H Lundbeck As | Method for the preparation of nalmefene hydrochloride |
| WO2011020030A2 (en) * | 2009-08-13 | 2011-02-17 | The General Hospital Corporation | Methods and compositions to prevent addiction |
| WO2011136376A1 (ja) | 2010-04-30 | 2011-11-03 | 武田薬品工業株式会社 | 腸溶性錠剤 |
| RS55777B1 (sr) | 2010-11-05 | 2017-07-31 | H Lundbeck As | Postupak za proizvodnju naltreksona |
| JP6406713B2 (ja) * | 2013-01-30 | 2018-10-17 | ファーモレックス セラピューティクス， インコーポレイテッド | 低用量薬剤によるうつ病および他の疾患の処置 |
| WO2014170351A1 (en) * | 2013-04-17 | 2014-10-23 | H. Lundbeck A/S | Nalmefene for treatment of patients with mood disorder |
| CA2909506C (en) | 2013-04-17 | 2021-04-20 | H. Lundbeck A/S | Nalmefene for treatment of patients with anxiety disorder |
-
2014
- 2014-12-18 MX MX2016007947A patent/MX368870B/es active IP Right Grant
- 2014-12-18 WO PCT/EP2014/078515 patent/WO2015091833A1/en not_active Ceased
- 2014-12-18 JP JP2016540981A patent/JP6448645B2/ja active Active
- 2014-12-18 ES ES14818973.1T patent/ES2694352T3/es active Active
- 2014-12-18 RU RU2016123972A patent/RU2679661C1/ru not_active IP Right Cessation
- 2014-12-18 SG SG11201604944PA patent/SG11201604944PA/en unknown
- 2014-12-18 CA CA2933733A patent/CA2933733A1/en not_active Abandoned
- 2014-12-18 AU AU2014368548A patent/AU2014368548B2/en not_active Ceased
- 2014-12-18 US US15/105,701 patent/US10376506B2/en active Active
- 2014-12-18 EP EP14818973.1A patent/EP3082815B1/en active Active
- 2014-12-18 CN CN201480069586.5A patent/CN105828821B/zh active Active
- 2014-12-18 KR KR1020167016182A patent/KR20160093025A/ko not_active Withdrawn
-
2016
- 2016-06-15 IL IL246253A patent/IL246253A0/en unknown
- 2016-06-17 CL CL2016001570A patent/CL2016001570A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160093025A (ko) | 2016-08-05 |
| ES2694352T3 (es) | 2018-12-20 |
| CA2933733A1 (en) | 2015-06-25 |
| JP6448645B2 (ja) | 2019-01-09 |
| AU2014368548A1 (en) | 2016-06-30 |
| SG11201604944PA (en) | 2016-07-28 |
| CL2016001570A1 (es) | 2016-12-09 |
| MX2016007947A (es) | 2016-09-09 |
| EP3082815A1 (en) | 2016-10-26 |
| AU2014368548B2 (en) | 2019-09-19 |
| JP2016540030A (ja) | 2016-12-22 |
| US20160310488A1 (en) | 2016-10-27 |
| EP3082815B1 (en) | 2018-10-03 |
| CN105828821A (zh) | 2016-08-03 |
| US10376506B2 (en) | 2019-08-13 |
| MX368870B (es) | 2019-10-21 |
| RU2016123972A (ru) | 2018-01-25 |
| WO2015091833A1 (en) | 2015-06-25 |
| CN105828821B (zh) | 2019-04-09 |
| RU2679661C1 (ru) | 2019-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200048I1 (hu) | FcRn antagonisták és alkalmazásaik | |
| IL272279A (en) | Chimeric antigen receptor and methods of using it | |
| IL273688A (en) | Evaluation and treatment of bradykinin-mediated disorders | |
| TWI560180B (en) | Substituted benzamides and methods of use thereof | |
| SG11201604944PA (en) | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features | |
| LT2970473T (lt) | Dr5 agonisto ir anti-pd-1 antagonisto derinys ir naudojimo būdai | |
| PT3637254T (pt) | Dispositivo portátil e método para restringir a utilização do dispositivo portátil | |
| SG11201600028YA (en) | Substituted aminopyrimidine compounds and methods of use | |
| IL252547A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| IL245493A0 (en) | Antibodies and methods of use | |
| PL2837591T3 (pl) | Przyrząd przewlekający snowarskiej ramy natykowej i sposób jego użycia | |
| GB2513304B (en) | Peripheral apparatus and method of construction | |
| IL240820A0 (en) | Substances that regulate a decrease in androgen receptor and their uses | |
| IL240014A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| SG11201507276UA (en) | Improved methods of use for recombinant human secretoglobins | |
| PT3071194T (pt) | Tratamento farmacológico de transtorno obcessivo-compulsivo utilizando estiripentol ou um composto semelhante | |
| GB201302105D0 (en) | Cover Means and Method of Use Thereof |